Use of standard criteria for assessment of cancer vaccines

Affiliations

Comment

Nicholas P Restifo et al. Lancet Oncol. 2005 Jan.

. 2005 Jan;6(1):3-4.

doi: 10.1016/S1470-2045(04)01693-6.

¹ US National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. restifo@nih.gov <restifo@nih.gov>

No abstract available

Conflict of interest statement

We declare no conflicts of interest.

Part I: Vaccines for solid tumours.
Mocellin S, Mandruzzato S, Bronte V, Lise M, Nitti D. Mocellin S, et al. Lancet Oncol. 2004 Nov;5(11):681-9. doi: 10.1016/S1470-2045(04)01610-9. Lancet Oncol. 2004. PMID: 15522656 Review.

1. Rosenberg SA, Dudley ME. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci USA. 2004;101 (suppl 2):14639–45. - PMC - PubMed
1. Klebanoff CA, Finkelstein SE, Surman DR, et al. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci USA. 2004;101:1969–74. - PMC - PubMed
1. Overwijk WW, Theoret MR, Finkelstein SE, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med. 2003;198:569–80. - PMC - PubMed
1. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10:909–15. - PMC - PubMed
1. Mocellin S, Mandruzzato S, Bronte V, et al. Part I: Vaccines for solid tumours. Lancet Oncol. 2004;5:681–89. - PubMed